Background: Recent trials suggest that disease-modifying therapy (DMT) for Alzheimer’s
disease may become available soon. With the expected high price and a large patient pool, the budget
impact will be substantial.
Objective: We explore combinations of effectiveness and price under which a DMT is cost-effective.
Methods: We used an open-source model to conduct two-way scenario analyses for both payer and societal
perspectives, varying price, and treatment effect size simultaneously. The analysis generates costeffectiveness
threshold prices over a potential range of DMT effectiveness in patients aged 65+ with
mild cognitive impairment due to Alzheimer’s disease in the US.
Results: Under the willingness-to-pay a threshold of $150,000 per quality-adjusted life year and assuming
30% risk reduction relative to the standard of care, the maximum cost-effective price of a DMT per
patient per year is ~$22,000 and ~$15,000 from societal and payer perspectives, respectively.
Conclusion: Joint variation of price and treatment effect size can help assess the cost-effectiveness of a
potential Alzheimer’s disease treatment.